Nektar should be climbing but this fast?
Nektar (NKTR) is another one of those stocks that looks to be moving up more strongly right now than the relatively sparse news would explain. Shares of this biotech are up 18.96% in the last week and 24.37% for the last 3 months. I can see a stream of positive news...
FDA and Nektar both shock on company’s opioid drug candidate; I’d buy more on weakness
Yesterday an advisory joint committee at the U.S. Food & Drug Administration voted to reject Nektar’s application for its new non-addictive opioid NKTR-181. The thinking–my thinking–was that the committee had structured the vote so that the most...
Nektar’s new non-addictive opioid NKTR-181 to finally get an FDA advisory vote tomorrow
I understand why the U.S. Food & Drug Administration has moved so slowly on a decision on Nektar Therapeutic’s (NKTR) new non-addictive opioid NKTR-181. The last thing the FDA wants to do in the midst of epidemic of opioid addiction is to approve a drug...
Nektar’s plunge is a buying opportunity–so I’m adding more to my Volatility Portfolio
What we know about Nektar Therapeutics (NKTR) is pretty clear. On Thursday of last week, August 8, trading in shares of Nektar were halted on news from the company had manufacturing problems that resulted in some patients enrolled in the clinical trials for the...
Nektar Therapeutics bumps along ahead of August FDA action on new non-addictive opioid
Shares of Nektar Therapeutics (NKTR) have been bumping along between $32 and $34 for two months now, but the company continues to take steps to prepare for the likely August approval of NKTR-181, a new non-addictive opioid. Nektar has formed Inheris Biopharma, a...
Updating Nektar ahead of a dangerous earnings season–and looking to add to positions on any plunge
On April 4 I made Nektar Therapeutics (NKTR) #8 in my list of the 10 most dangerous stocks for earnings season and #4 on my list of 5 stock to buy on any plunge in my Special Report on my JubakAm.com subscription site. Here’s what I wrote in that Special...
What a difference a week makes for biotech stocks
Last week the biotech sector seemed in freewill. Bristol Myers Squibb (BMY) had made a deal to buy Celgene (CELG) at a whopping 54% premium to Wednesday’s close and the sector dropped on the news. The prevailing theory was that the deal removed one hungry big...
Why Nektar is extremely oversold right now
The longs and the shorts continue to battle over Nektar Therapeutics (NKTR.) Right now the shorts have the best of that fight. No contest. The shares of this biotech fell another 1.24% today to close at $51.71. A little more than a month ago they were at $68.49. But I...
Nektar beats on earnings–more importantly FDA accepts company’s new opioid for review
I wrote this post while on vacation in an effort to use this down time to catch up on earnings results that I missed during the very busy second quarter earning season. This post was written on August 18. After the market close on Wednesday, August 8,...
Nektar’s 40% drop yesterday was an extreme over-reaction: What I’m doing now
It’s never good to turn in disappointing results in a drug trial–as Nektar Therapeutics (NKTR) did over the weekend–but to whack 40% off the stock price on this news is an extreme over-reaction. To justify a 40% drop you have to assume 1) that the...
Stock or options, Nektar needs some understanding and patience now
It hasn’t exactly been a stellar couple of months for shares and options on Nektar Therapeutics (NKTR). The stock, which I hold in my Jubak Picks portfolio, is down 23.1% since it hit a high of $108.44 on March 8. The August 17, 2018 call options with a strike...
Positive catalysts are intact for Nektar Therapeutics
Shares of biotech rocket Nektar Therapeutics (NKTR) are down 23.25% since they traded at $106.91 on March 21, 2018. I can’t find evidence that the positive catalysts that led me to recommend the stock for my Jubak Picks portfolio and the options for my...
Nektar blows away revenue projections, gives very positive guidance on drug pipeline
Shares of Nektar Therapeutics (NKTR) finished up 21.67% today to $102.87 after the biotech company announced after the close yesterday a smaller than expected fourth quarter 2017 loss of 21 cents a share (versus the Wall Street consensus projection of a 36 cents a...
Bristol-Myers puts up potential $3.6 billion in deal for 35% of a Nektar cancer drug
In the deal announced today Bristol-Myers Squibb (BMY) pays Nektar Therapeutics $1 billion upfront, $850 million for stock valued at a price of $102 a share, and a potential $1.78 billlion in milestone payments in exchange for access to NKTR 214, a drug candidate...
On the second day of Christmas my stock pick for 2018 is Nektar Therapeutics–and two-turtle doves
No point in hoping that Nektar Therapeutics (NKTR) will match this year’s gain of 364% as of the close on December 18. But I think the stock could easily climb another 30% or more in 2018 as the company de-risks its very promising drug candidates in the opioid...
Nektar soared today on cancer drug data–but remember that new opioid? That’s why I say “Buy” in Jubak Picks even after this run
Nektar Therapeutics (NKTR) shares finished the day up 14.15% on fairly preliminary, but very important data from the trials of the company’s lead cancer drug. Those results go a long way to validating the company’s entire pipeline of drug candidates to...Jim’s Daily Email Alerts:
Every post from Jubak Picks straight to your mailbox. And they're free!